Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 66
GLP-1 patients primarily switch from OADs and untapped
potential is large with many OAD patients not in control
GLP-1 source of business
(new-to-brand prescription market share)
Insulin and Treatment
Share of patients on OADs achieving
HbA1c below 7% in major European countries
GLP-1
naïve
5% 5%
Insulin
29%
51%
GLP-1
9%
OAD
HbA1c >7%
43%
57%
HbA1c <7%
Note: Data based on data from France, Germany, UK and USA only
OAD: Oral anti-diabetic (includes but is not limited to DPP-IV, SGLT-2, metformin and sulfonylurea)
Source: IQVIA (formerly IMS) Disease Analyser (France, Germany and UK) and IQVIA (formerly IMS) LRX
(USA), Sep 2017
Note: Data based on data from France, Germany and UK only
Source: IQVIA (formerly IMS) Disease Analyser (France, Germany and UK), Sep 2017
novo nordiskView entire presentation